The 9th International Symposium on Myelodysplastic Syndromes, Florence, Italy, May 16-19, 2007
MDS 2007
Titolo
Sponsored by the Myelodysplastic Syndromes Foundation
Scientific Program
Scientific Program
(DOWNLOAD FINAL PROGRAM)
Wednesday, May 16, 2007
16:00-19.00 - Opening Lectures on Myelodysplastic Syndromes
Chairmen: P. Greenberg, M. Tomonaga
16:00-16:45 U. Germing: Epidemiologic features of myelodysplastic syndromes
16:45-17:30 J. Bennett: Classification of primary myelodysplastic syndromes
17:30-18:15 J. Pedersen-Bjergaard: Therapy-related myelodysplasia
18:15-19:00 T.E. Quill: Susanne Fleischman Memorial Lecture: Communicating evidence for participatory decision making
19:00 - Opening Ceremony & Welcome Party
Thursday, May 17, 2007
8:30-10:00 – Molecular Basis and Pathophysiology of Myelodysplastic Syndromes (I)
Chairman: T. Hamblin
8:30-9:00 R.A. Padua: Animal models of myelodysplasia
9:00-9:30 S.D. Nimer: Insights into the molecular pathogenesis of myelodysplastic syndromes
9:30-10:00 N.S. Young: The immune pathophysiology of bone marrow failure and the emergence of clonal hematologic diseases
10:00-10:30 - Coffee Break
10:30-12:00 - Molecular Basis and Pathophysiology of Myelodysplastic Syndromes (II)
Chairman: C. Niemeyer
10:30-11:00 D. Steensma: Acquired thalassemia in myelodysplastic syndrome: rare curiosity, or revealing condition?
11:00-11:30 J. Boultwood: Molecular analysis of the 5q- syndrome
11:30-12:00 M. Cazzola: Refractory anemia with ringed sideroblasts
12:00-13:30 – Symposium on Multi-Targeted Therapy of Myelodysplastic Syndromes and Acute Myeloid Leukemia (sponsored by Pharmion)
Chairman: M. Baccarani
12:00-12:20 V. Santini: DNA methyltransferase inhibition in the therapy of myelodysplastic syndromes
12:20-12:40 G. Garcia-Manero: Combination epigenetic therapy
12:40-13:00 J.F. Seymour: Treatment of myelodysplastic syndromes with azacitidine and thalidomide
13:00-13:20 S. Nand: Treatment of acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly with azacitidine and gemtuzumab ozogamicin
13:20-13:30 M. Baccarani: Conclusions
13:30-14:30 - Open time for lunch
14:30-16:00 – Symposium on Lenalidomide – Changing the MDS Treatment Paradigm (sponsored by Celgene)
Chairmen: E. Morra, P. Fenaux
14:30-14:35 E. Morra: Introduction
14:35-14:55 G. Mufti: Cytogenetics of myelodysplastic syndromes and detection of del 5q
14:55-15:15 A. List: Active treatment – improving outcome in del 5q patients
15:15-15:30 C. Schiffer: Treating non-del 5q patients with lenalidomide
15:30-15:45 A.A. Giagounidis: Practical management of lenalidomide
15:45-16:00 P. Fenaux (moderator): The MDS treatment paradigm – time for a change? Panel discussion /challenging debate
16:00-18:00 - Simultaneous Oral Sessions (Session I: Epidemiology and Classification – Session II: Diagnosis and Prognosis)
18:00-19:30 - Poster Sessions
Friday, May 18, 2007
8:30-10:00 - Clonal Proliferation and Clonal Dominance in Myeloid Disorders
Chairman: C. Mecucci
8:30-9:00 R. Notaro: Paroxysmal nocturnal hemoglobinuria
9:00-9:30 R. Skoda: Genetics of chronic myeloproliferative disorders
9:30-10:00 B. Falini: Acute myeloid leukaemia carrying cytoplasmic mutated nucleophosmin (NPMc+ AML): molecular and clinico-pathological features
10:00-10:30 - Coffee break
10:30-12:00 - Novel Diagnostic and Prognostic Tools
Chairman: C. Aul
10:30-11:00 M.G. Della Porta: Flow cytometry immunophenotyping
11:00-11:30 J. Wainscoat: Molecular markers
11:30-12:00 L. Malcovati: WPSS, a dynamic prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
12:00-13:30 – Symposium on Iron Overload and Survival of Patients with Myelodysplastic Syndrome (sponsored by Novartis)
Chairman: M. Cazzola
12:00-12:20 L. Malcovati: Impact of transfusion dependency and secondary iron overload of the survival of patients with myelodysplastic syndrome
12:20-12:40 H. A. Leitch: Improved survival in MDS patients receiving iron chelation therapy
12:40-13:00 N. Gattermann: Guidelines on iron chelation therapy in patients with myelodysplastic syndrome and transfusion iron overload
13:00-13:20 S. L. Goldberg: Deferasirox – the novel, once a day oral iron chelator
13:20-13:30 Panel discussion/debate
13:30-14:30 - Open Time for Lunch
14:30-15:30 – Ineffective Hematopoiesis and the Use of Hematopoietic Growth Factors in Myelodysplastic Syndromes (session supported by an unrestricted educational grant from Roche)
Chairman: A. Ganser
14:30-15:00 R. Invernizzi: Increased apoptosis as a mechanism of ineffective hematopoiesis in myelodysplastic syndromes
15:00-15:30 E. Hellström-Lindberg: Treatment of myelodysplastic syndromes with erythropoietin and G-CSF
15:30-16:00 – The Growing Importance of Hematopoietic Growth Factors in Myelodysplastic Syndromes (session supported by an unrestricted educational grant from Amgen)
Chairman: P. Greenberg
15:30-16:00 D.T. Bowen: Hematopoietic growth factors in the treatment of neutropenia and thrombocytopenia of myelodysplastic syndromes.
16:00-18:00 - Simultaneous Oral Sessions (Session I: Molecular Mechanisms and Pathophysiology– Session II: Treatment)
18:00-19:30 - Poster Sessions
Saturday, May 19, 2007
8:30-10:30 – Evidence-Based Treatment of Myelodysplastic Syndromes (I, session supported by an unrestricted educational grant from Janssen-Cilag)
Chairman: E. Estey
8:30-9:00 P. Fenaux: Which MDS patients are candidates for treatment with hematopoietic growth factors?
9:00-9:30 G. Sanz: Which MDS patients are candidates for aggressive chemotherapy?
9:30-10:00 D.T. Bowen: Is traditional low dose chemotherapy (cytarabine/melphalan) still an option?
10:00-10:30 M. Lübbert: Which MDS patients are candidates for treatment with decitabine?
10:30-11:00: Coffee Break
11:00-12:45 - Evidence-Based Treatment of Myelodysplastic Syndromes (II)
Chairman: A. Bosi
11:00-11:30 L.R. Silverman: Which MDS patients are candidates for treatment with azacitidine?
11:30-12:00 S.D. Gore: Do histone deacetylase inhibitors have a place in the treatment of myelodysplastic syndromes?
12:00-12:45 T. De Witte: Which MDS patients are candidates for transplantation?
12.45 Closing Remarks
M. Cazzola, N. Zoumbos